TrialSignal transduction and targeted therapy2026

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.

Wenjing Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.